Clinical Trial Update: Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Galvus (vildagliptin) as add-on to metformin and glimepiride in type 2 diabetes; safety and efficacy results reported after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Galvus (vildagliptin)
• Glimepiride (glimepiride)
• metformin (metformin)

Snippet

Sponsor: Novartis | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED